Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbbVie Inc (ABBV) vs Enbridge Inc (ENB) Price & Performance

AbbVie IncTrade
Enbridge IncTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs Enbridge Inc — how do they compare? AbbVie Inc trades at $250 (market cap $438.19B), while Enbridge Inc trades at $51.68 (market cap $112.26B). The key difference: AbbVie Inc is far larger — about 3.9× Enbridge Inc's market cap, and Enbridge Inc pays the higher dividend (5.36%). Which is the better fit depends on your goals.

ABBVENB
Market Cap
$438.19B$112.26B
Sector
HealthEnergy
52-Week High
$263.58$58.04
52-Week Low
$197.38$45.23
Enterprise Value
$502.45B$196.07B
Dividend Yield
2.79%5.36%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

Enbridge Inc

ENB trades at $51.28, down 0.81% on the day, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $0.46, beating estimates, and maintains a strong dividend track record with recent payouts of $0.97. Revenue grew to $65.19B in 2025, with a net income margin of 7.34%, though debt levels have increased.

Outlook is mixed; analyst consensus is evenly split between Buy and Hold, with a 48% Buy rating. Key opportunities include a $41B project backlog and consistent dividend growth, while risks involve high debt, regulatory challenges, and volatile cash flows. The stock's valuation appears reasonable with a P/E of 27.74.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Read more on ABBV

About Enbridge Inc

Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.

Read more on ENB